Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …

Lysine-specific demethylase 6A (KDM6A), also named UTX, is frequently mutated in bladder
cancer (BCa). Although known as a tumor suppressor, KDM6A's therapeutic potential in the …

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …

We sought to define whether there are intrinsic molecular subtypes of high-grade bladder
cancer. Consensus clustering performed on gene expression data from a meta-dataset of …

Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups.
Patients with localized disease can be cured with surgical resection or radiotherapy, but …

Major clinical issues in bladder cancer include the identification of prediction markers and
novel therapeutic targets for invasive bladder cancer. In the current study, we describe the …

Whole-genome analyses have revealed that muscle-invasive bladder cancers (MIBCs) are
heterogeneous and can be grouped into basal and luminal subtypes that are highly …

Genomic profiling studies have demonstrated that bladder cancer can be divided into two
molecular subtypes referred to as luminal and basal with distinct clinical behaviors and …

Context Recent whole genome mRNA expression profiling studies revealed that bladder
cancers can be grouped into molecular subtypes, some of which share clinical properties …